<DOC>
	<DOCNO>NCT00296816</DOCNO>
	<brief_summary>Feasibility study ass novel combination cytotoxic agent , docetaxel oxaliplatin , first-line therapy treatment ovarian cancer impact angiogenesis inhibition progression prognosis ovarian cancer concurrent addition bevacizumab ( Avastin® ) .</brief_summary>
	<brief_title>TEACO : Taxotere , Eloxatin , Avastin Cancer Ovary</brief_title>
	<detailed_description>Participants - administer study medication approximately 28 day initial surgery ovarian cancer - receive study treatment regimen one year unless disease progression , unacceptable toxicity , death , participant refusal , treatment delay beyond time frame permit treatment Participants follow survival minimum 3 year date enrollment</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Females 18 year age old 2 . Participants histologic diagnosis ovarian , primary peritoneal , fallopian tube carcinoma , Stage Ib IV , either optimal ( ≤ 1 cm residual disease ) suboptimal residual disease ( &gt; 1 cm maximal diameter remain lesion ) follow initial surgery . 3 . Participants follow histologic epithelial cell type eligible : Serious adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant Brenner 's Tumor , adenocarcinoma N.O.S . 4 . Participant must adequate bone marrow function 5 . Participant must adequate renal function 6 . Participant must adequate urine protein/creatinine reaction ( UPC ) &lt; 1.0 ; 7 . Participant must adequate neurologic function 8 . Hepatic function : Total Bilirubin ≤ ULN ; AST ALT Alkaline Phosphatase must within range allow eligibility . In determine eligibility abnormal two value ( AST ALT ) use . 9 . Blood Coagulation parameter : PT international normalize ratio ( INR ) &lt; 1.5 ( inrange INR , usually 2 3 , participant stable dose therapeutic Warfarin low molecular weight heparin ) PTT &lt; 1.2 time upper limit normal . 10 . Participants must enrol study prior 50 day ( every effort make prior 28 day ) initial surgery perform combined purpose diagnosis , stag cytoreduction . 11 . Participants measurable nonmeasurable disease eligible . Participants suboptimal disease eligible . Participants may may cancerrelated symptom . 12 . Participants meet preentry requirement specify include serologic measurement CA125 baseline subsequent determination response use Rustin criterion . 13 . Participants GOG Performance Status 0 , 1 , 2 . EXCLUSION CRITERIA : 1 . Participants current diagnosis epithelial ovarian tumor low malignant potential ( Borderline carcinoma ) eligible . Participants prior diagnosis low malignant potential tumor surgically resect subsequently develop invasive adenocarcinoma eligible , provide receive prior chemotherapy ovarian tumor . 2 . Germ cell tumor , sex cordstromal tumor , carcinosarcoma , mixed mullerian tumor carcinosarcomas , metastatic carcinoma site ovary low malignant potential tumor include call micropapillary serous carcinoma eligible . 3 . Participants receive prior radiotherapy portion abdominal cavity pelvis exclude . Prior radiation localize cancer skin permit , provide complete 5 year prior enrollment , participant remain free recurrent metastatic disease . 4 . Participants receive prior anticancer chemotherapy biologic therapy malignancy exclude . 5 . Participants synchronous primary endometrial cancer , past history primary endometrial cancer , exclude , unless follow condition meet : Stage great IB ; Less 3 mm invasion without vascular lymphatic invasion ; No poorly differentiate subtypes , include papillary serous , clear cell , FIGO Grade 3 lesion . 6 . Participants history cancer , exception inclusion criterion # 2 # 3 , nonmelanoma skin cancer , cancer free last 5 year , exclude . 7 . Participant acute hepatitis active infection require parenteral antibiotic . 8 . Participants serious , nonhealing wound , ulcer , bone fracture . This include history abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day . Participants granulate incision heal secondary intention evidence fascial dehiscence infection eligible require weekly wound examination . 9 . Participants active bleed pathologic condition carry high risk bleeding , know bleed disorder , coagulopathy , tumor involve major vessel . 10 . Participants history evidence upon physical examination CNS disease , include primary brain tumor , seizures control standard medical therapy , brain metastasis , history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarachnoid hemorrhage within six month first date treatment study . 11 . Participants clinically significant cardiovascular disease . 12 . Participants clinically significant proteinuria . Urine protein screen urinalysis . Participants discover urine protein : serum creatinine ratio great equal 1 undergo 24hour urine collection , must adequate collection must demonstrate &lt; 1000 mg protein/24 hr allow participation study . 13 . Participants anticipation invasive procedure . 14 . Participants GOG Performance Grade 3 4 . 15 . Participants pregnant nursing . 16 . Participants know hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibody hypersensitivity polysorbate 80 hypersensitivity study drug ingredient . 17 . Participants participate study investigational product/device within last 30 day . 18 . Any medical condition judgment investigator would jeopardize participant safety study drug evaluation efficacy safety .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>